化合物 T13366 T13366

Product Introduction
Bioactivity


英文名: YHO-13351

描述: YHO-13351 is the water-soluble prodrug of YHO-13177, which is a potent and specific BCRP inhibitor.

体外活性: YHO-13177 enhances SN-38, mitoxantrone and topotecan in BCRP transduced human colon cancer HCT116 (HCT116/BCRP) cells and BCRP-expressing SN-38 resistant human lung cancer A549 (A549/SN4) Cytotoxicity in cells, but little effect on parental cells. In addition, YHO-13177 potentiates the cytotoxicity of SN-38 in human lung cancer NCI-H460 and NCI-H23, myeloma RPMI-8226, and pancreatic cancer AsPC-1 cells that intrinsically expressed BCRP. YHO-13177 increases the intracellular accumulation of Hoechst 33342, a substrate of BCRP, at 30 minutes and partially suppresses the expression of BCRP protein at more than 24 hours after its treatment in both HCT116/BCRP and A549/SN4 cells .

体内活性: YHO-13351 was rapidly converted into YHO-13177 after its oral or intravenous administration In mice. Coadministration of irinotecan with YHO-13351 significantly increased the survival time of mice inoculated with BCRP-transduced murine leukemia P388 cells and suppressed the tumor growth in an HCT116/BCRP xenograft model, whereas irinotecan alone had little effect in these tumor models .

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 38 mg/mL (65.55 mM)


关键字: YHO 13351 | YHO13351 | YHO-13351

相关产品: FT001 | Cycloastragenol | PROTAC BRD4 ligand-1 | 1-benzyl-2-ethyl-4,5,6,7-tetrahydro-1H-indol-4-one | RVX-297 | BRD4 Inhibitor-10 | MS436 | BRD4 Inhibitor-24 | MG 149 | NSC 228155

化合物 T13366 T13366信息由TargetMol中国为您提供，如您想了解更多关于化合物 T13366 T13366报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途